RORgamma Modulators for Autoimmune Disease Treatment
Solution Overview
Problem
Current treatments for autoimmune and inflammatory diseases associated with RORγ, such as rheumatoid arthritis and psoriasis, lack effective small molecule ligands that can modulate RORγ activity, leading to inadequate therapeutic options.
Innovation Solution
Development of small molecule RORγ modulators that bind to the RORγ receptor, specifically compounds of Formula (1), which can act as agonists or antagonists to regulate RORγ activity, thereby treating or preventing RORγ-mediated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for autoimmune and inflammatory diseases are used, then existing therapeutic options are available, but effective small molecule ligands that can modulate RORγ activity are lacking
Solution Approach 1:
The patent applies parameter changes by developing small molecule compounds with specific chemical structures (Formula I) that can bind to RORγ and modulate its transcriptional activity. The compounds feature variable substituents (R1-R6, Ar, X, Y, Z) that can be optimized to achieve desired agonist or antagonist effects, enabling precise control of RORγ activity for therapeutic purposes
2Object-affected harmful factors
If RORγ activity is reduced to treat autoimmune diseases, then immune response is shifted and symptoms are alleviated, but new therapeutic compounds must be developed
Solution Approach 1:
The patent segments the therapeutic approach by creating a series of related compounds based on Formula I with different substituent patterns. This modular structure allows systematic optimization of individual compounds for specific disease indications while maintaining the core mechanism of RORγ modulation, facilitating both development and manufacturing
3Reliability
If small molecule RORγ modulators are developed, then effective treatment options are created, but compound structure complexity increases
Solution Approach 1:
The patent achieves universality by designing a core molecular framework (Formula I) that can function as both agonist and antagonist depending on substituent configuration. This multi-functional design allows a single compound series to address multiple therapeutic needs (different autoimmune and inflammatory conditions) without requiring entirely separate molecular architectures
Data Source
Figure 1a~1b
Figure 1c
Figure 2a
AI summary
The invention provides modulators for the orphan nuclear receptor ROR? and methods for treating ROR? mediated diseases by administrating these novel ROR? modulators to a human or a mammal in need thereof. Specifically, the present invention provides compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.
